Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 83; no. 5; pp. 680 - 682
Main Authors Schiff, Abigail E, Wang, Xiaosong, Patel, Naomi J, Kawano, Yumeko, Hanberg, Jennifer L, Kowalski, Emily N, Cook, Claire E, Vanni, Kathleen MM, Qian, Grace, Bade, Katarina J, Saavedra, Alene A, Srivatsan, Shruthi, Williams, Zachary K, Venkat, Rathnam K, Wallace, Zachary S, Sparks, Jeffrey A
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and European League Against Rheumatism 01.05.2024
BMJ Publishing Group LTD
Subjects
Antibodies
Arthritis, Rheumatoid
Autoimmune diseases
Cohort analysis
Consent
COVID-19
COVID-19 vaccines
Drug dosages
Epidemiology
Immunomodulation
Immunomodulators
Letter
Lung diseases
mRNA
mRNA vaccines
Patients
Rheumatoid arthritis
Rituximab
Severe acute respiratory syndrome coronavirus 2
Survival analysis
TNF inhibitors
Tumor necrosis factor-TNF
Vaccination
United States > US
Rituximab
Covid-19
Epidemiology
Vaccination
Arthritis, Rheumatoid
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0003-4967
1468-2060
DOI:10.1136/ard-2023-225162